Barclays Initiates Coverage On Medtronic with Equal-Weight Rating, Announces Price Target of $95
Barclays analyst Christopher Pasquale initiates coverage on Medtronic (NYSE:MDT) with a Equal-Weight rating and announces Price Target of $95.
Stocks · News reference
TD Cowen Reiterates Buy on Medtronic, Maintains $110 Price Target
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight
The global bioelectronic medicine market is projected to grow from USD 8.9 billion in 2025 to USD 21.6 billion by 2034, driven by increasing adoption of neuromodulation technologies, advances in implantable devices, AI integration, and expanding applications beyond neurological disorders. North America leads the market with 44% share, while Asia-Pacific is expected to record the fastest growth rate.
Medtronic Receives American Medical Association Approval For Category I Current Procedural Terminology Codes For Two Its Technologies
Medtronic Receives FDA Clearance, CE Mark For Its Affera Prism-2 Mapping Software, Also Receives CE Mark For PulseSelect ProxBox Adapter